

**DEVELOPMENT AND EVALUATION  
OF A NASBA SYSTEM  
FOR THE DIAGNOSIS OF CHOLERA  
USING ELISA AND BIOSENSOR METHODS**

**LEE SU YIN**

**UNIVERSITI SAINS MALAYSIA**

**2008**

**DEVELOPMENT AND EVALUATION OF A  
NASBA SYSTEM FOR THE DIAGNOSIS OF CHOLERA  
USING ELISA AND BIOSENSOR METHODS**

**by**

**LEE SU YIN**

**Thesis submitted in fulfillment of the  
requirements for the degree of  
Doctor of Philosophy**

**April 2008**

## ACKNOWLEDGEMENTS

I would like to express my deepest gratitude to my supervisor, Dr P. Lalitha, who has been helpful and supportive throughout this study. Her critical comments and valuable insights have guided me in the preparation of this thesis. I am grateful to my co-supervisor, Prof. Zainul F. Zainuddin and Assoc. Prof. M. Ravichandran for their guidance and advice that have motivated me to become a better student and researcher.

To my dear friends and comrades, Melissa Chan, Yean Yean and Kurunathan, I express my heartfelt appreciation for their encouragements and support that have helped me through numerous failed experiments and mental roadblocks. My appreciation also goes out to my labmates and friends who have helped me in one way or another during the course of this study: Elina, Balqis, Donn, Chua, Siew Keah, Nik, Nurul, Kak Shikin, Nas, Nisha, Chandrika, Syazwan, Kun Lee, Narjit and Kavitha. In addition, I am grateful to the lecturers, administrative staff and lab technologists from the Department of Medical Microbiology and Parasitology, and Institute for Research in Molecular Medicine, Universiti Sains Malaysia for their help and the use of their excellent facilities.

I would like to thank Prof. Mitsuaki Nishibuchi from the Center for Southeast Asia Studies, Kyoto University, Japan; Communicable Disease Hospital, Thandiarpettai, Chennai, India; National Public Health Laboratory, Ministry of Health, Malaysia; Institute for Medical Research (IMR), Malaysia and Kak Liza from the Medical Microbiology and Parasitology laboratory, Universiti Sains Malaysia for providing the various bacterial strains used in this study. I am also grateful to the Ministry of Science, Technology and Innovations (MOSTI) for the IRPA and NBD grants that have funded part of this study.

On a more personal note, my family has been my strongest motivation and inspiration. No words could ever express my gratitude to them. As a sign of appreciation, I dedicate this thesis to them and hope that I have made them proud.

## TABLE OF CONTENTS

Acknowledgement.....	ii
Table of Contents.....	iii
List of Tables.....	ix
List of Figures.....	x
List of Symbols, Abbreviations and Acronyms.....	xiii
Abstrak.....	xvii
Abstract.....	xix

### CHAPTER 1 - INTRODUCTION

1.1	History of cholera .....	1
1.2	Prevalence of cholera .....	1
1.3	Characteristics of <i>V. cholerae</i> .....	2
1.4	Ecology of <i>V. cholerae</i> .....	5
1.5	Viable but non-culturable (VBNC) state .....	5
1.6	Epidemiology of cholera.....	6
1.7	Pathophysiology of cholera.....	6
1.8	Clinical manifestations of cholera .....	7
1.9	Treatment of cholera .....	8
1.10	Prevention of cholera .....	8
1.11	Diagnosis of cholera .....	9
1.11.1	Conventional laboratory methods.....	9
1.11.2	Alternative methods of cholera diagnosis.....	11
1.11.2.1	Immunological-based tests for cholera .....	11
1.11.2.2	Molecular-based tests for cholera .....	12
1.11.2.2.1	Characteristics and advantages of molecular-based tests over conventional methods.....	13
1.11.2.3	Nucleic acid sequence-based amplification (NASBA) .....	14
1.12	Rationale of the study .....	17
1.13	Objectives of the study.....	18
1.14	Overview of the study.....	19

## CHAPTER 2 – MATERIALS AND METHODS

2.1	Materials .....	20
2.1.1	Bacterial strains.....	20
2.1.1.1	Reference strains .....	20
2.1.1.2	Clinical isolates .....	20
2.1.1.3	Growth and maintenance of bacterial strains .....	21
2.1.2	Culture Media .....	21
2.1.3	Primers and probes.....	25
2.1.3.1	Preparation of primer stock solutions.....	25
2.1.3.2	Preparation of primer working solutions.....	25
2.1.4	Deoxyribonucleotide triphosphates (dNTP, 20 $\mu$ M) .....	25
2.1.5	Ribonucleotides (NTP, 20 $\mu$ M) .....	26
2.1.6	Buffers and chemical stock solutions .....	26
2.1.6.1	Diethylpyrocarbonate (DEPC) treatment of water and solutions.....	27
2.1.6.2	Diethylpyrocarbonate (DEPC) treatment of glasswares and plasticwares .....	27
2.2	Methods .....	27
2.2.1	RNA Isolation .....	27
2.2.2	Quantitation of RNA.....	28
2.2.3	Plasmid Isolation.....	29
2.2.4	Genomic DNA Isolation .....	29
2.2.5	Quantitation of DNA .....	30
2.2.6	Polymerase Chain Reaction (PCR) assay .....	31
2.2.7	Purification of PCR product.....	31
2.2.8	Agarose gel electrophoresis .....	32
2.3	Experimental overview of Phase 1 study: Development and optimization of a cholera NASBA assay.....	35
2.3.1	Designing primers and probes for cholera NASBA assay .....	36
2.3.2	Construction of <i>in vitro</i> RNA transcripts.....	38
2.3.2.1	Cloning of <i>V. cholerae</i> <i>lolB</i> gene.....	38
2.3.2.2	PCR of the <i>lolB</i> gene.....	38
2.3.2.3	Ligation of PCR product into pTZ57R vector .....	38
2.3.2.4	Preparation of competent <i>E. coli</i> Top10 cells .....	40
2.3.2.5	Transformation.....	40
2.3.2.6	PCR screening of transformed colonies .....	41
2.3.2.7	DNA sequencing .....	43

2.3.2.8	Plasmid linearization by restriction endonuclease digestion.....	43
2.3.2.9	<i>In vitro</i> transcription.....	43
2.3.2.10	Purification of RNA using phenol-chloroform and ethanol precipitation.....	44
2.3.3	Cholera NASBA assay .....	46
2.3.3.1	Preparation of cholera NASBA reaction mix and enzyme mix .....	46
2.3.3.2	Detection of NASBA amplicons by agarose gel electrophoresis.....	49
2.3.3.3	Optimization of cholera NASBA reaction conditions.....	49
2.3.3.4	Analytical specificity of the cholera NASBA assay .....	51
2.3.3.5	Analytical sensitivity of the cholera NASBA assay.....	51
2.3.3.5.1	Analytical sensitivity at the gene level.....	51
2.3.3.5.2	Analytical sensitivity at the bacterial cell level.....	52
2.3.3.6	Reproducibility and efficiency of the RNA isolation technique .....	53
2.3.4	Analysis of the NASBA reaction and its amplicons .....	54
2.3.4.1	Northern Blotting .....	54
2.3.4.2	Dot-blotting.....	55
2.3.4.2.1	Hybridization with biotinylated DNA probe.....	55
2.3.4.2.2	Hybridization with Streptavidin-HRP .....	56
2.3.4.2.3	Colorimetric detection of blots.....	56
2.3.4.3	RNase and DNase digestion of NASBA amplicons.....	57
2.3.4.4	Amplification of DNA by NASBA.....	59
2.3.4.5	Viability assay.....	59
2.4	Experimental overview of Phase 2 study : Development and optimization of ELISA for detection of NASBA amplicons (NASBA-ELISA).....	61
2.4.1	Cholera NASBA-ELISA assay.....	62
2.4.1.1	Preparation of 3'-end biotin-tailed capture probe (VHA-S4-Biotin3').....	64
2.4.1.2	Optimization and comparison of the hybridization efficiency of 3'-end biotin-tailed capture probe (VHA-S4-Biotin3') and 5'-end biotin- labelled capture probe (VHA-S4-5'Biotin).....	64
2.4.1.3	Optimization of VN2F-Flu concentration as detection probe for unlabelled NASBA amplicons .....	65
2.4.1.4	Optimization of fluorescein-12-UTP concentration for internal labeling of NASBA amplicons.....	65
2.4.1.5	Detection of NASBA amplicons by ELISA.....	65
2.4.1.6	Analytical specificity of the cholera NASBA-ELISA assays .....	67
2.4.1.7	Analytical sensitivity of the cholera NASBA-ELISA assays .....	67

2.4.2	Clinical evaluation of cholera NASBA-ELISA using spiked stool samples .....	68
2.4.2.1	Preparation of spiked stool samples .....	68
2.4.2.2	Limit of detection (LoD) of cholera NASBA-ELISA at the bacterial cell level using spiked stool samples .....	69
2.4.2.3	Statistical analysis .....	69
2.4.2.3.1	Calculation of sample size for spiked stool sample evaluation .....	69
2.4.3.3.2	Calculation of diagnostic performance for spiked stool sample evaluation .....	70
2.5	Experimental overview of Phase 3 study: Development of electrochemical biosensor detection for cholera NASBA-ELISA .....	71
2.5.1	Biosensor detection for cholera NASBA-ELISA .....	72
2.5.1.1	Biosensor and electrode design .....	72
2.5.1.2	Optimization of biosensor detection of cholera NASBA-ELISA signal .....	72
2.5.1.3	Analytical specificity of the cholera NASBA-ELISA with biosensor detection .....	73
2.5.1.4	Analytical sensitivity of the cholera NASBA-ELISA with biosensor detection .....	73
2.6	Experimental overview of Phase 4 study: Optimization of a thermostabilized cholera NASBA mix .....	75
2.6.1	Thermostabilization of cholera NASBA mix (reaction mix and enzyme mix) .....	76
2.6.1.1	Preparation of freeze-dried reaction mix .....	76
2.6.1.2	Preparation of freeze-dried enzyme mix .....	77
2.6.1.2.1	Optimization of enzymes and enzyme stabilizer concentrations .....	77
2.6.1.3	Freeze-drying of NASBA reaction and enzyme mixes .....	77
2.6.1.4	Reconstitution of the freeze-dried NASBA mix .....	78
2.6.1.5	Analytical sensitivity of the freeze-dried cholera NASBA mix at the bacterial cell level .....	78
2.6.1.6	Determination of periodic stability of the freeze-dried cholera NASBA mix at different temperatures .....	79

## CHAPTER 3 – RESULTS AND DISCUSSION

3.1	Designing primers and probes for cholera NASBA assay .....	80
3.2	Construction of RNA transcript .....	84
3.2.1	Cloning of <i>lolB</i> gene into pTZ57R vector .....	84
3.2.2	Confirmation of clones by PCR screening and DNA sequencing .....	86
3.2.3	<i>In vitro</i> transcription of the linearized pTZ- <i>lolB</i> plasmid .....	89
3.3	Cholera NASBA assay .....	91
3.3.1	Optimization of cholera NASBA reaction conditions .....	91
3.3.1.1	MgCl <sub>2</sub> concentration .....	91
3.3.1.2	KCl concentration .....	91
3.3.1.3	Primers concentration .....	93
3.3.1.4	DMSO concentration .....	93
3.3.1.5	Enzymes concentration .....	95
3.3.2	Detection of NASBA amplicons by agarose gel electrophoresis .....	98
3.3.3	Analytical specificity of the cholera NASBA assay .....	98
3.3.4	Analytical sensitivity of the cholera NASBA assay .....	100
3.3.5	Reproducibility and efficiency of the RNA isolation technique .....	103
3.3.6	Analysis of the NASBA reaction and its amplicons .....	105
3.3.6.1	Probe-based hybridization of NASBA amplicons .....	105
3.3.6.1.1	Northern Blotting .....	105
3.3.6.1.2	Dot-blotting .....	105
3.3.6.2	RNase and DNase digestion of NASBA amplicons .....	107
3.3.6.3	Amplification of DNA by NASBA .....	109
3.3.6.4	Viability assay .....	111
3.4	Cholera NASBA-ELISA .....	113
3.4.1	Optimization and comparison of 3'-end biotin-tailed capture probe (VHA-S4-Biotin3') and 5'-end biotin-labelled capture probes (VHA-S4-'Biotin) .....	113
3.4.2	Optimization of VN2F-Flu concentration as detection probe for unlabelled NASBA amplicons .....	115
3.4.3	Optimization of fluorescein-12-UTP concentration for internal labeling of NASBA amplicons .....	117
3.4.5	Analytical specificity of the two NABSA-ELISA formats .....	119
3.4.6	Analytical sensitivity of the two NASBA-ELISA formats at the gene and bacterial cell level .....	122
3.4.7	Comparison of performance of the two NASBA-ELISA formats .....	126



3.4.8	Evaluation of cholera NASBA-ELISA using spiked stool samples .....	128
3.4.8.1	Diagnostic performance of the cholera NASBA-ELISA assay.....	131
3.4.8.2	Limit of detection (LoD) of cholera NASBA-ELISA at the bacterial cell level using spiked stool samples .....	131
3.5	Electrochemical biosensor detection of cholera NASBA-ELISA .....	134
3.5.1	Analytical specificity of the cholera NASBA-ELISA assay with biosensor detection .....	134
3.5.2	Analytical sensitivity of the cholera NASBA-ELISA assay with biosensor detection .....	137
3.5.3	Comparison and correlation between biosensor- and spectrophotometric- based ELISA results.....	139
3.6	Thermostabilization of cholera NASBA mix .....	141
3.6.1	Optimization of enzymes and enzyme stabilizer concentrations .....	141
3.6.2	Analytical sensitivity of the freeze-dried NASBA mix at the bacterial cell and gene level.....	144
3.6.3	Periodic stability of the freeze-dried NASBA mix .....	146
3.7	Discussion.....	148
<b>CHAPTER 4 – SUMMARY AND CONCLUSION .....</b>		<b>167</b>
<b>REFERENCES.....</b>		<b>170</b>
<b>APPENDICES</b>		
Appendix A – Preparation of Culture Media, Buffers and Chemical Stock Solutions.....		A1
Appendix B – Alignment result of <i>V. cholerae lolB</i> gene (AF227752) with the <i>lolB</i> or <i>hemM</i> gene of other enteric bacteria.....		A11
Appendix C – <i>lolB</i> ( <i>hemM</i> ) sequence (Genbank accession no: AF227752) and NASBA primers and probes binding sites.....		A16
Appendix D – Partial sequence of pTZ- <i>lolB</i> plasmid (position 551 – 1350) showing the binding sites of primers used for PCR screening of clones and restriction enzymes sites.....		A17
Appendix E – Alignment of pTZ- <i>lolB</i> sequencing result with the <i>lolB</i> gene sequence (AF227752).....		A18
<b>LIST OF PUBLICATIONS</b>		

## LIST OF TABLES

Table 1.1: Tests for differentiation of Classical and El Tor biotypes of <i>V. cholerae</i> serogroup O1.....	4
Table 1.2: <i>V. cholerae</i> serogroups and their antigenic determinants .....	4
Table 2.1: Details of the reference strains used in this study.....	22
Table 2.2: Details of the clinical isolates used in this study .....	23
Table 2.3: Composition of a standard PCR mix .....	34
Table 2.4: Standard thermal cycling programme.....	34
Table 2.6: Details of the cholera NASBA primers and probes used in this study.....	37
Table 2.5: Details of PCR primers, annealing temperatures and expected product sizes used in the PCR screening of transformed colonies.....	42
Table 2.7: Composition of the cholera NASBA mix before optimization.....	48
Table 2.8: Optimization of cholera NASBA reaction components.....	50
Table 3.1: Result of PCR screening for two positive pTZ- <i>lolB</i> clones to confirm the gene insert size and orientation.....	88
Table 3.2: Composition of the optimized cholera NASBA mix .....	97
Table 3.3: Reproducibility of the RNA isolation technique. RNA isolation was performed on a culture of <i>V. cholerae</i> O1 El Tor in six replicates. ....	104
Table 3.4: Efficiency of the RNA isolation technique. RNA isolation was performed on four replicate samples spiked with 10 µg of RNA from <i>V. cholerae</i> O1 El Tor. ....	104
Table 3.5: Reproducibility of NASBA-ELISA using unlabelled and labelled NASBA amplicons based on the analytical sensitivity assays .....	127
Table 3.6: Summary of cholera NASBA-ELISA evaluation with spiked stool samples.....	130
Table 3.7: Statistical analysis of the diagnostic performance of the cholera NASBA-ELISA.....	132

## LIST OF FIGURES

Figure 2.1: Procedures involved in the cloning of <i>lolB</i> gene of <i>V. cholerae</i> .....	39
Figure 2.2: Plasmid map of pTZ- <i>lolB</i> showing the exact position of the cloning site, genetic elements, restriction sites and T7 promoter site.....	39
Figure 2.3: <i>In vitro</i> transcription of the <i>SacI</i> linearized pTZ- <i>lolB</i> plasmid to produce RNA transcripts .....	45
Figure 2.4: Procedures involved in NASBA and detection of its amplicons by agarose gel electrophoresis.....	47
Figure 2.5: Procedures involved in the viability assay to determine whether the <i>lolB</i> mRNA can be used as an indicator of cell viability.....	60
Figure 2.6: Diagrammatic representation of the two ELISA formats evaluated in this study using unlabelled NASBA amplicons (A) or fluorescein-labelled NASBA amplicons (B). .....	63
Figure 2.7: Experimental overview of the cholera NASBA-ELISA assay with biosensor detection. ....	74
Figure 3.1: Mfold result showing a possible structure for the 784 nucleotide region of the <i>lolB</i> mRNA molecule and the NASBA primers binding sites.....	82
Figure 3.2: Mfold result showing a possible structure of the 203 nucleotide NASBA amplicon and probes binding sites.....	83
Figure 3.3: Agarose gel electrophoresis result of the <i>lolB</i> gene PCR product for cloning into pTZ57R vector .....	85
Figure 3.4: PCR screening of two positive clones for the correct <i>lolB</i> gene insert size and orientation. ....	87
Figure 3.5: Linearization of pTZ- <i>lolB</i> plasmid with <i>SacI</i> enzyme .....	90
Figure 3.6: <i>In vitro</i> transcription of linearized pTZ- <i>lolB</i> plasmid .....	90
Figure 3.7: Optimization of MgCl <sub>2</sub> concentration .....	92
Figure 3.8: Optimization of KCl concentration .....	92
Figure 3.9: Optimization of primers concentration.....	94
Figure 3.10: Optimization of DMSO concentration .....	94
Figure 3.11: Optimization of T7 RNA polymerase (A) and AMV-RT (B) enzymes concentration .....	96
Figure 3.12: Analytical specificity evaluation of the cholera NASBA assay with agarose gel electrophoresis detection.....	99
Figure 3.13: Analytical sensitivity of the cholera NASBA assay at the gene level using agarose gel electrophoresis detection.....	101

Figure 3.14: Analytical sensitivity of the cholera NASBA assay at the bacterial cell level using agarose gel electrophoresis detection .....	102
Figure 3.15: Northern blotting of NASBA amplicons from agarose gel (A) onto a positively-charged nylon membrane (B).....	106
Figure 3.16: Dot-blotting of NASBA amplicons onto a positively-charged nylon membrane.....	106
Figure 3.17: Analysis of NASBA amplicons by RNase A and DNase I digestion.....	108
Figure 3.18: Analysis of RNase A and DNase I digested NASBA amplicons by RT-PCR (A) and PCR (B) .....	108
Figure 3.19: Amplification of DNA by NASBA .....	110
Figure 3.20: Evaluation of the stability of the <i>l</i> o <i>B</i> mRNA after lethal treatments and incubation at different times and temperatures. ....	112
Figure 3.21: Comparison of ELISA signal using 3'-end (VHA-S4-Biotin3') and 5'-end (VHA-S4-5'Biotin) biotin-labelled capture probes.....	114
Figure 3.22: Optimization of VN2F-Flu detection probe concentration using unlabelled NASBA amplicons from positive control .....	116
Figure 3.23: Optimization of fluorescein-12-UTP concentration using <i>l</i> o <i>B</i> RNA transcripts with amplicon detection by agarose gel electrophoresis(A) and ELISA(B)....	118
Figure 3.24: Analytical specificity of ELISA detection using unlabelled NASBA amplicons evaluated using a panel of 41 reference bacterial strains. ....	120
Figure 3.25: Analytical specificity of ELISA detection using fluorescein-labelled NASBA amplicons evaluated using a panel of 41 reference bacterial strains.....	121
Figure 3.26: Analytical sensitivity of NASBA-ELISA at the (A) gene and (B) bacterial cell level using unlabelled and fluorescein-labelled NASBA amplicons.....	123
Figure 3.27: Analytical sensitivity at the gene level using unlabelled (A) and fluorescein-labelled (B) NASBA amplicons by agarose gel electrophoresis.....	124
Figure 3.28: Analytical sensitivity at the bacterial cell level using unlabelled (A) and fluorescein-labelled (B) NASBA amplicons by agarose gel electrophoresis...	125
Figure 3.29: Clinical evaluation of cholera NASBA-ELISA using spiked stool samples..	129
Figure 3.30: Limit of detection (LoD) of cholera NASBA-ELISA at the bacterial cell level with spiked stool samples.....	133
Figure 3.31: Analytical specificity of cholera NASBA-ELISA with signal measurement by spectrophotometry (microplate reader) and biosensor .....	136
Figure 3.32: Analytical sensitivity of NASBA-ELISA at the gene (A) and bacterial cell (B) level with signal measurement by spectrophotometry (microplate reader) and biosensor .....	138

Figure 3.33: Correlation analysis of biosensor and spectrophotometry results. ....	140
Figure 3.34: First round optimization of enzymes and enzyme stabilizer concentrations for thermostabilization of enzyme mix. ....	142
Figure 3.35: Second round optimization of enzymes and enzyme stabilizer concentrations for thermostabilization of enzyme mix. ....	142
Figure 3.36: Optimization using higher concentrations of enzyme stabilizer for thermostabilization of enzyme mix. ....	143
Figure 3.37: Analytical sensitivity of the freeze-dried NASBA mix at the bacterial cell level (A) and gene level (B). ....	145
Figure 3.38: Periodic evaluation of the stability of freeze-dried NASBA mix.....	147

## LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMS

Symbols/ Abbreviations/ Acronyms	Definition	Symbols/ Abbreviations / Acronyms	Definition
--	nil	cDNA	complimentary deoxyribonucleic acid
%	percent	CFU	colony forming unit
~	approximately	Cl <sup>-</sup>	chlorine ion
+	positive	cm	centimeter
-	negative/ minus	CT	cholera toxin
<	less than	CTP	cytidine 5'-triphosphate
>	more than	CV	coefficient of variation
±	plus / minus	dATP	deoxyadenosine triphosphate
→	to	dCTP	deoxycytidine triphosphate
°C	degree Celsius	ddt	dideoxythymidine
A	adenine / adenosine; absorbance	DEPC	diethylpyrocarbonate
A <sub>260</sub>	absorbance at 260 nm	dG	Gibbs free energy
A <sub>280</sub>	absorbance at 280 nm	dGTP	deoxyguanosine triphosphate
A <sub>450</sub>	absorbance at 450 nm	dH <sub>2</sub> O	distilled water
ADP	adenosine diphosphate	DMSO	dimethyl sulfoxide
Ag/AgCl	silver/silver chloride	DNA	deoxyribonucleic acid
AMV-RT	avian myeloblastosis virus- reverse transcriptase	DNase	deoxyribonuclease
APW	alkaline peptone water	dNTP	deoxynucleoside triphosphate
ATP	adenosine 5'-triphosphate	DTT	dithiothreitol
BLAST	Basic Local Alignment Search Tool	dTTP	deoxythymidine triphosphate
bp	basepair	ECL	electrochemiluminescence
BSA	bovine serum albumin	EDTA	ethylenediaminetetraacetic acid
C	cytosine; current	ELGA	enzyme-linked gel assay
cAMP	adenosine 3',5'-cyclic monophosphate	ELISA	enzyme-linked immunosorbent assay

<i>et al.</i>	et alii / and other	IU	infectious unit; international unit
FAM	carboxyfluorescein	J	Joule
FDA	Food and Drug Administration	<i>k</i>	kappa value
Flu	fluorescein	K <sup>+</sup>	potassium ion
G	guanine / guanosine	kcal/mol	kilocalories per mol
g	gram	KCl	potassium chloride
GHKB	General Hospital Kota Bharu	kDa	kilodalton
GITC	guanidine thiocyanate	KIA	Kligler iron agar
GM1	monosialotetrahexosylganglioside	L/hour	liter per hour
GMO	genetically modified organism	LB	Luria Bertani
GTP	guanosine 5'-triphosphate	LCD	liquid crystal display
H <sub>2</sub>	hydrogen	LCR	ligase chain reaction
H <sub>2</sub> O	water	LoD	limit of detection
H <sub>2</sub> O <sub>2</sub>	hydrogen peroxidase	M	molar / molarity
H <sub>2</sub> S	hydrogen sulphate	mbar	millibar
HCl	hydrogen chloride	MCS	multiple cloning site
HCO <sub>3</sub> <sup>-</sup>	hydrogen carbonate ion	mg	milligram
HIV-1	human immunodeficiency virus 1	MgCl <sub>2</sub>	magnesium chloride
HPLC	high performance liquid chromatography	min	minute
hr	hour	MKAK	National Public Health Laboratory
HRP	horseradish peroxidase	ml	milliliter
HUSM	Hospital Universiti Sains Malaysia	mm	millimeter
i.e.	<i>id est</i> / that is	mM	millimolar
IFU	inclusion-forming unit	M-MLV RT	Moloney murine leukemia virus reverse transcriptase
IMR	Institute for Medical Research	MOPS	3-( <i>N</i> -morpholino)propanesulfonic
IPA	intermittent pulse amperometry	mRNA	messenger ribonucleic acid

N	normal	psi	pounds per square inch
n	sample size	p <sub>sn</sub>	specificity
N/A	not available / not applicable	p <sub>sp</sub>	sensitivity
Na <sup>+</sup>	sodium ion	R <sup>2</sup>	correlation coefficient
NAD	nicotinamide	red	reduced / reduction
NaOH	sodium hydroxide	RNA	ribonucleic acid
NASBA	nucleic acid sequence-based amplification	RNase	ribonuclease
NCBI	National Center for Biotechnology Information	RNase H	Ribonuclease H
nm	nanometer	RNasin	RNasin Ribonuclease Inhibitor
nmol	nanomol	rpm	revolutions per minute
NPV	negative predictive value	rRNA	ribosomal ribonucleic acid
nt	nucleotide	RSD	relative standard deviation
NTP	nucleoside triphosphate	RT	room temperature
O <sub>2</sub>	oxygen	RT-PCR	reverse transcription-polymerase chain reaction
OD	optical density	S	Svedberg unit
OD <sub>450</sub>	optical density at 450 nm	SAM	self-assembled monolayer
OD <sub>600</sub>	optical density at 600 nm	SD	standard deviation
OH	hydroxyl group	SDA	strand displacement amplification
ORS	oral rehydration solution	SDS	sodium dodecyl sulphate
ox	oxidized / oxidation	s	second
PBS	phosphate buffered saline	SPCE	screen-printed carbon electrode
PBST	phosphate buffered saline-Tween 20	SPE	screen-printed electrode
PCR	polymerase chain reaction	spp.	species
PFU	PCR-forming unit	SPR	surface plasmon resonance
pmol	picomole	SSC	sodium chloride/sodium citrate
PPV	positive predictive value	SSCT	sodium chloride/sodium citrate/Tween 20



T	thymine / thymidine	UTP	uridine 5'-triphosphate
Ta	annealing temperature	UV	ultraviolet
TAE	Tris-acetate-EDTA	V	volts
TBE	Tris-borate-EDTA	v/v	volume/volume
TCBS	thiosulphate citrate bilesalt sucrose	VBNC	viable but non-culturable
tcp	toxin coregulated pili	vs	versus
TdT	terminal deoxynucleotidyl transferase	w/v	weight/volume
TE	Tris-EDTA	www	World Wide Web
Tm	melting temperature	x	precision
TMA	transcription-mediated amplification	x g	relative centrifugal force
TMB	3,3',5,5'- tetramethylbenzidine	μA	microamperes
Tris	tris(hydroxymethyl)aminomet hane	μg	microgram
tRNA	transfer ribonucleic acid	μl	microliter
TSI	triple sugar indole	μm	micrometer
U	units	μM	micromolar

**PEMBANGUNAN DAN PENILAIAN SISTEM NASBA UNTUK DIAGNOSIS  
PENYAKIT TAUN MENGGUNAKAN KAEDAH ELISA DAN BIOSENSOR**

**ABSTRAK**

Taun (kolera) ialah penyakit ciri-birit yang disebabkan *Vibrio cholerae*. Taun boleh membawa maut jika tidak dikesan dengan serta-merta. Justeru, pengesanan awal adalah penting untuk rawatan pesakit dan kawalan wabak taun. Ujian kultur dan biokimia konvensional adalah rumit, lambat dan kurang sensitif. Walaupun ujian berasaskan teknik molekul adalah lebih pantas, sensitif dan spesifik, kaedah ini memerlukan peralatan mahal dan penyimpanan sejuk bahan-bahan reagen. Ujian DNA seperti PCR tidak dapat membezakan sel hidup dengan sel mati. Kaedah amplifikasi berasaskan asid nukleik (NASBA) yang menggandakan RNA secara isoterma dapat mengesan sel hidup sahaja. Maka, objektif kajian ini adalah untuk membangunkan dan menilai suatu ujian NASBA-ELISA yang stabil haba dengan *biosensor* untuk mengesan *V. cholerae* berasaskan gen *lolB*. Pada peringkat permulaan, transkrip RNA sebagai kawalan positif dikonstruksi dan primer serta prob khusus direka. Pengoptimuman ujian NASBA dan ELISA dilakukan dan spesifisiti analitikal diuji dengan 41 bakteria rujukan yang terdiri daripada *V. cholerae*, *Vibrio* spesis dan patogen enterik. Sensitiviti analitikal diuji dengan cairan bersiri transkrip RNA dan sel-sel *V. cholerae*. Penilaian klinikal dijalankan dengan menggunakan najis yang ditokok sampel (n=200). Seterusnya, kaedah *biosensor* dioptimumkan dan keputusannya dibandingkan dengan kaedah spektrofotometri. Campuran NASBA dijadikan stabil haba melalui pengeringbekuan dan kestabilannya dinilai pada suhu berlainan untuk jangkamasa tertentu. Selain itu, kesesuaian *lolB* mRNA sebagai penunjuk kebolehhidupan diselidiki dengan membunuh sel-sel *V. cholerae* melalui pelbagai kaedah dan mengesan isyarat NASBA daripadanya. Ujian kolera NASBA-ELISA yang telah dioptimumkan berdasarkan pengesanan produk amplifikasi melalui prob berlabel *fluorescein* dan isyarat TMB/HRP. Spesifisiti analitikal ujian adalah 100% manakala sensitiviti analitikal ujian adalah  $10^2$

molekul/ $\mu$ l transkrip RNA dan 10 CFU/ml sel. Penilaian klinikal memberikan keputusan 100% sensitif, 84.52% spesifik, 89.92% nilai ramalan positif dan 100% nilai ramalan negatif. Kaedah *biosensor* didapati setanding kaedah spektrofotometri dengan mencatatkan kepekaan analitikal yang sama, korelasi yang rapat ( $R^2 < 0.964$ ) dan persetujuan kappa yang hampir sempurna (95.1%,  $k = 0.828$ ). Penstabilan campuran NASBA mampu mengekalkan kestabilannya pada 8°C dan -20°C selama dua bulan. Dalam ujian kebolehhidupan sel, gen *lolB* masih dapat dikesan daripada kultur sel *V. cholerae* yang telah dibunuh selepas 48 jam, justeru gen ini tidak sesuai dijadikan penunjuk sel bernyawa. Kesimpulannya, buat pertama kalinya, kami telah membangunkan suatu ujian kolera-NASBA-ELISA dengan pengesanan *biosensor* yang sensitif dan dapat dilakukan dengan peralatan mudah dalam empat jam. Campuran NASBA kering mengurangkan langkah-langkah mempipet serta memudahkan penghantaran dan penyimpanan ujian. Ujian ini sesuai sebagai ujian diagnostik pantas dan ujian saringan di lapangan.

## **DEVELOPMENT AND EVALUATION OF A NASBA SYSTEM FOR THE DIAGNOSIS OF CHOLERA USING ELISA AND BIOSENSOR METHODS**

### **ABSTRACT**

Cholera is a diarrheal disease caused by *Vibrio cholerae*. Cholera is potentially lethal if not diagnosed on time. Hence, early detection is crucial for patient treatment and containment of outbreak. Conventional culture and biochemical tests are laborious, time-consuming and less sensitive. Although molecular-based methods are rapid, more sensitive and specific; they require expensive equipments and cold storage of reagents. Furthermore, DNA-based tests such as PCR, do not distinguish between viable and non-viable cells. Nucleic acid sequence-based amplification (NASBA) is an isothermal RNA amplification technique that specifically detects viable cells. Hence, the objective of this study was to develop and evaluate a thermostabilized cholera-NASBA-ELISA assay with biosensor detection for *V. cholerae* based on the *lolB* gene. RNA transcripts as positive control were first constructed and specific primers and probes were designed. NASBA and ELISA conditions were optimized and the analytical specificity was tested with 41 reference strains comprising of *V. cholerae*, *Vibrio* species and enteric pathogens. The analytical sensitivity was tested with serial dilutions of RNA transcripts and *V. cholerae* cells. Clinical evaluation of the assay was performed using spiked stool samples (n=200). Subsequently, biosensor detection for the NASBA-ELISA assay was optimized and the results compared to spectrophotometry. The NASBA mix was thermostabilized by freeze-drying and its stability at different temperatures was determined periodically. In addition, suitability of *lolB* mRNA as a viability indicator was investigated by subjecting cultures to lethal treatments and detecting the NASBA signal. The optimized cholera-NASBA-ELISA assay detected amplicons using fluorescein-labeled probes and TMB/HRP signal. The analytical specificity of the assay was 100%, while the analytical sensitivity was  $10^2$  molecules/ $\mu$ l RNA transcripts and 10 CFU/ml cells. Clinical evaluation gave 100%

sensitivity, 84.52% specificity, 89.92% PPV and 100% NPV. Biosensor detection was comparable to spectrophotometry, yielding similar analytical sensitivity level, excellent correlation ( $R^2 < 0.964$ ) and near perfect kappa agreement (95.1%,  $k = 0.828$ ). Thermostabilization of the NASBA mix was able to preserve its stability at 8°C and -20°C for two months. In the viability assay, *lolB* mRNA was detected even after 48 hours post-treatment, therefore precluding its use as a viability indicator. In conclusion, we have for the first time, developed a sensitive cholera-NASBA-ELISA assay with biosensor detection that can be performed using simple equipments within four hours. The dry NASBA mix reduces multiple pipetting steps and facilitates transportation and storage. The test is suitable for use as a rapid diagnostic test or screening test in the field.

## **CHAPTER 1**

### **INTRODUCTION**

#### **1.1 History of cholera**

Cholera is a potentially life-threatening secretory diarrheal disease caused by the bacteria *Vibrio cholerae*. Cholera is thought to originate from the Ganges Delta of the Indian subcontinent. In the nineteenth century, seven distinct pandemic waves of cholera spread from Asia to many parts of the world. Six pandemics arose from the Indian subcontinent, while the seventh pandemic originated from the island of Sulawesi, Indonesia in 1961 (Parsi, 2001). In the late 1992, a possible eighth pandemic was reported when a large epidemic cholera spread throughout Bangladesh, India, Pakistan, Nepal, China, Thailand and Malaysia (Blake, 1994).

There are more than 150 serogroups of *V. cholerae*, however only the serogroups O1 and O139 cause epidemic and pandemic diseases (Sack *et al.*, 2004). The Classical biotype of *V. cholerae* serogroup O1 was responsible for the fifth and sixth pandemics and is believed to have been associated with the earlier pandemics as well. The seventh cholera pandemic is caused by the El Tor biotype of *V. cholerae* serogroup O1 and this biotype has completely displaced the Classical biotype worldwide, except in Bangladesh where it appeared in epidemic proportions in 1982 and now seems to have become extinct again (WHO, 2002). The newly emerged serogroup O139 or 'Bengal' in the late 1992 has been attributed to the eighth cholera pandemic and this serogroup is closely related to the Asian *V. cholerae* O1 El Tor strains associated with the seventh pandemic (Blake, 1994).

#### **1.2 Prevalence of cholera**

Cholera is one of the oldest and best-known diseases in the world, yet it continues to cause considerable suffering and needless deaths. In 2006 alone 131,943 cases of cholera were reported worldwide with 2272 fatalities (WHO, 2007). However, this number is just the tip of the iceberg because poor surveillance and fear of travel and economic sanctions lead to

under-reporting of actual cholera cases in certain countries (WHO, 2007). It is estimated that in reality, the number of deaths from cholera is probably 100 times more than was officially reported (WHO, 2007). In Malaysia, the Ministry of Health reported the incidence rate of cholera in 2005 (per 100,000 population) was 1.48 with a 0.01 mortality rate (Ministry of Health Malaysia, July 2007).

### **1.3 Characteristics of *V. cholerae***

*Vibrio cholerae* is a member of the family *Vibrionaceae*. It is a facultative anaerobe, short, curved rod about 1.4 – 2.6 µm, capable of fermentative and respiratory metabolism. It is a non-halophilic vibrio, oxidase-positive, reduces nitrate and is highly motile by means of a single sheathed polar flagellum. Even though growth of *V. cholerae* is stimulated by addition of 1% sodium chloride, it can grow in nutrient broth without added sodium chloride, which is an important distinction from other *Vibrio* spp. (Kay *et al.*, 1994). It can grow at 16 – 40°C, with an optimum temperature of 37°C and at pH 7.4 – 9.6 (WHO, 2002).

The species *V. cholerae* is divided into more than 150 serogroups based on the differences in their somatic (O) antigens. These variations are secondary to differences in the oligosaccharide side chains in parts of the cell wall (Parsi, 2001). The serogroup O1 is divided into two biotypes, Classical and El Tor, which can be differentiated by tests such as hemolysis, hemagglutination, phage typing, polymyxin B sensitivity and Voges-Proskauer reaction (table 1.1). Each of the O1 biotype can be further subdivided into two major serotypes, Ogawa and Inaba, based on variations in the polysaccharide component of the O antigen. Ogawa strains possess only the A and B antigens while Inaba strains possess only the A and C antigens. A third and rare serotype, Hikojima possesses all three A, B and C antigens (Kay *et al.*, 1994).

The new serogroup O139 Bengal was thought to have evolved as a result of horizontal gene transfer between O1 and non-O1 strains. The O139 strain does not produce O1 lipopolysaccharide and lacks some of the genetic material necessary for production of the O1 antigen. It has potential for capsule expression and an increased capacity for spread and proliferation within the environment (Morris and Cholera Laboratory Task Force, 1994).

Strains of *V. cholerae* identified by biochemical tests but do not agglutinate with O1 and O139 antisera are referred to as non-O1, non-O139 *V. cholerae*. The non-O1, non-O139 strains can produce enterotoxins that are similar to cholera toxin (Morris, 1994). Although this strain is not involved in cholera epidemics, it can be pathogenic and is frequently associated with small sporadic outbreaks of diarrheal disease caused by the consumption of contaminated shellfish and from a variety of extraintestinal infections (Morris, 1994).

Besides the somatic (O) antigen, all *V. cholerae* possess common heat-labile flagella (H) antigen, and this property may be used to distinguish *V. cholerae* from all other vibrios (Kay *et al.*, 1994). Table 1.2 summarizes the different *V. cholerae* serogroups and their antigenic determinants.



**Table 1.1: Tests for differentiation of Classical and El Tor biotypes of *V. cholerae* serogroup O1**

Test / Reaction	Biotype	
	Classical	El Tor
Hemolysis of sheep erythrocytes	–	+
Hemagglutination with fowl erythrocytes	–	+
Susceptibility to bacteriophage:		
i) classical phage (group IV)	+	–
ii) El Tor phage (group V)	–	+
Sensitivity to Polymyxin B (50 U)	+	–
Produces acetoin in Voges Proskauer test (modified with 1% NaCl)	–	+

**Table 1.2: *V. cholerae* serogroups and their antigenic determinants**

Typing systems	Epidemic associated		Non-epidemic associated
	O1	O139	Non-O1
<b>Serogroup</b>	O1	O139	Non-O1
<b>Biotypes</b>	Classical El Tor	None	–
<b>Serotypes</b>	Ogawa Inaba Hikojima	None	None
<b>O1 Antigens</b>	Ogawa – A and B Inaba – A and C Hikojima – A, B and C	Does not have O1 somatic antigen	Does not have O1 somatic antigen
<b>Toxin production</b>	Produces cholera toxin	Produces cholera toxin	Usually does not produce cholera toxin, sometimes produce other toxins
<b>Polysaccharide capsule</b>	None	Yes	None

Adapted from Kay, B., Bopp, C. & Wells, J. (1994) In *Vibrio cholerae* and Cholera: Molecular to global perspectives (Eds, Wachsmuth, I., Blake, P. and Olsvik, O.) American Society for Microbiology, Washington DC (table 1, pp. 4)

#### **1.4 Ecology of *V. cholerae***

Until the late 1970s and early 1980s, it was believed that *V. cholerae* was highly host-dependant and incapable of surviving longer than a few hours or days outside the human intestine. However, studies have shown that *V. cholerae* is a normal inhabitant of brackish water and estuarine systems (Colwell and Huq, 1994a). *V. cholerae* non-O1, non-O139 strains are frequently isolated from aquatic ecosystems while O1 and O139 strains are less frequently isolated. Outside of the host and in the aquatic environment, *V. cholerae* can be found as free swimming cells, attached to aquatic plants, filamentous green algae, copepods, crustaceans, insects and egg masses of chironomids. Environmental persistence of *V. cholerae* within natural aquatic habitats during periods between epidemics is facilitated by biofilm formation and entry into a viable but non-culturable (VBNC) state (Colwell and Huq, 1994b).

#### **1.5 Viable but non-culturable (VBNC) state**

*V. cholerae* O1 and non-O1, non-O139 strains can enter into a VBNC state in response to nutrient deprivation, elevated salinity and reduced temperatures. In this dormant state, the *V. cholerae* cells are reduced in size, become ovoid and do not grow at all on standard laboratory media used to isolate *V. cholerae*. However, Colwell *et al.* (1994b) found that when the VBNC cells of *V. cholerae* were inoculated into rabbit ileal loops or ingested by human volunteers, it caused large accumulation of fluid in the rabbit ileal loops or diarrhea in the human volunteers. This may explain the reason attempts to culture and isolate *V. cholerae* from water sources between epidemics often fail. Since *V. cholerae* in the VBNC state in environmental samples may not grow on conventional bacteriologic media, it may go undetected unless other detection methods such as immunologic, molecular or direct microscopy are employed. Huq *et al.* (1990) showed that *V. cholerae* O1 could be detected by direct immunofluorescence microscopy throughout the year in their water reservoirs even when culturing could not isolate the organism itself. Rapid detection kits for *V. cholerae* that do not require culture called CholeraScreen (a coagglutination test), Cholera DFA (direct

fluorescent monoclonal antibody staining kit) and Cholera SMART (a colorimetric immunoassay) have been developed and these were also able to detect VBNC cells of *V. cholerae* (Colwell and Huq, 1994b).

### **1.6 Epidemiology of cholera**

Cholera is the classic water-borne disease and an epidemiological study by John Snow in 1849 showed the association of the disease with contaminated drinking water (Parsi, 2001). Poor sewerage and sanitation practices that resulted in contamination of water supplies used for drinking and food preparation are often the causes of cholera epidemics (Mintz *et al.*, 1994). This mode of transmission is more common in less developed countries under conditions of famine, war and natural disaster. Cholera transmission has also been linked to drinking water from shallow wells, rivers, bottled water and ice (Parsi, 2001).

Food is another vehicle for transmission. Seafood, particularly raw or undercooked shellfish harvested from sewage-contaminated seabeds, meat, cooked grains, fruit and vegetables irrigated with raw sewerage have been implicated in cholera outbreaks (Parsi, 2001, Mintz *et al.*, 1994).

### **1.7 Pathophysiology of cholera**

Upon ingestion, *V. cholerae* cells colonize the small intestines, particularly the duodenum and jejunum because the alkaline pH, nutrients and bile salts provide a suitable environment. They adhere to the microvilli with the help of a long filamentous fimbriae called toxin-coregulated pili (Tcp pili), hemagglutinins, mucinase and neuraminidase. Their motility also enables them to penetrate the mucus layer. They penetrate the host cells by elaborating a potent enterotoxin, called cholera toxin (CT), a 84 kDa protein consisting of 2 regions, which are the A region and B region (Sack *et al.*, 2004).

The B region (56 kDa) binds the glycolipid, GM1 ganglioside on the host intestinal epithelial cell membrane, enabling the A region (28 kDa) to penetrate the cell. The A region will enzymatically transfer ADP-ribose from NAD to a GTP-binding regulatory protein associated with membrane-bound adenylate cyclase enzyme. The ADP-ribosylation reaction activates adenylate cyclase, which leads to an increase of intracellular cAMP levels. This is followed by the secretion of H<sub>2</sub>O, Na<sup>+</sup>, K<sup>+</sup>, Cl<sup>-</sup> and HCO<sub>3</sub><sup>-</sup> into the lumen (Kaper *et al.*, 1994). The patient may lose several litres of protein-free fluid and associated electrolytes, bicarbonates and ions within hours. The watery diarrhea (rice-water stool) is speckled with flakes of mucus, epithelial cells and contains large number of vibrios. Excessive loss of fluid may lead to dehydration, uremia, metabolic acidosis, hypovolemic shock and subsequently, death in untreated cases (Sack *et al.*, 2004, Parsi, 2001). The severity of a cholera infection depends on many factors, and it is increased with the absence of a local intestinal immunity, a high infectious dose (>10<sup>8</sup> bacteria), low gastric acid production and possession of blood group O (Sack *et al.*, 2004, Parsi, 2001).

### **1.8 Clinical manifestations of cholera**

Most individuals infected with *V. cholerae* have no symptoms or only mild diarrhea, indistinguishable from other mild diarrheal diseases. Only a minority will develop cholera, a disease characterized by the sudden onset of vomiting and profuse watery diarrhea, following an incubation period of 6 to 48 hours. The most distinctive feature of cholera is the painless purging of voluminous stools resembling rice-water and having a fishy odour. In adults with severe cholera, the volume of watery stool may exceed 1 L/hour, leading to severe dehydration, hypovolemic shock, metabolic acidosis and renal failure. This condition may lead to death within a few hours of onset if rapid treatment is not given (Bennish, 1994, Parsi, 2001).

### **1.9 Treatment of cholera**

Without proper treatment the case-fatality for severe cholera is about 50% (Sack *et al.*, 2004). Treatment is very simple and effective based on fluid replacement. Oral rehydration solution (ORS) should be given for mild cases of diarrhea, while intravenous fluid replacement using lactated Ringer's solution should be given for more severe cases (Parsi, 2001). The use of antibiotics shortens the duration and severity of the illness. In most cases, tetracycline and doxycycline is the antibiotic of choice. In cases of tetracycline resistance, erythromycin, cotrimoxazole, ciprofloxacin, azithromycin and trimethoprim-sulfamethoxazole may be used (Parsi, 2001).

### **1.10 Prevention of cholera**

Transmission of *V. cholerae* through contaminated food and water can be prevented by minimizing contamination and reducing survival and growth of the organism (Sack *et al.*, 2004). The level of contamination can be minimized by practicing personal and domestic hygiene such as hand washing with soap before food handling and safe sewage disposal. Survival of the organism may be diminished by boiling or disinfecting drinking water and proper cooking and refrigeration of food. Prophylactic prevention of cholera can be achieved through the use of vaccines. Three oral vaccines (two inactivated and one live attenuated) are currently available (Sack *et al.*, 2004). These vaccines have been licensed in some countries and are mainly used by travellers. However, these vaccines are for *V. cholerae* serogroup O1 and do not give cross-protection against other serogroups such as O139 or non-O1, non-O139. Although a number of vaccine candidates for *V. cholerae* serogroup O139 are under development (Ravichandran *et al.*, 2006), they are not commercially available. Prevention of cholera using vaccines may be beneficial as a public health intervention if they are cost-effective, give long lasting protection and easy to administer.

## **1.11 Diagnosis of cholera**

### **1.11.1 Conventional laboratory methods**

Due to the clinical and epidemiological severity of cholera, rapid diagnosis of *V. cholerae* in clinical samples, water and food is very critical so that appropriate monitoring and effective preventive measures can be undertaken to prevent a cholera outbreak. The conventional laboratory methods employed are culturing, microscopy and biochemical testing.

Faecal specimens should be collected as early as possible in the illness, as the number of *V. cholerae* begins to decline soon after onset of symptoms, and before initiation of antibiotic therapy (Kay *et al.*, 1994). Faecal specimens or rectal swabs should be collected from patients into a sterile bottle containing transport medium such as alkaline peptone water (APW). APW is also the standard medium for enrichment of *V. cholerae* as its high pH condition preferentially supports the growth of vibrios while inhibiting other organisms and it can be used to recover low levels of vibrios in faecal specimens (Kay *et al.*, 1994).

If specimen is collected on the first day of illness, the vibrios are likely to be present in large numbers ( $10^7$ - $10^9$  CFU/ml), hence it is possible to make a provisional diagnosis by direct microscopy examination of a film of faeces using dark-field or phase-contrast microscopy (Kay *et al.*, 1994). Vibrios are highly motile and can be seen darting about rapidly. When specific antiserum is added to the film, the vibrios are immobilized.

For culture, fresh faecal specimens or APW-enriched specimens are plated onto thiosulfate-citrate-bile salts-sucrose (TCBS) agar, a highly differential and selective medium for *V. cholerae*. Its selective ingredients suppress the growth of most of the interfering organisms such as coliforms, pseudomonads, aeromonads and other Gram-positive bacteria (WHO, 2002). The sucrose-fermenting *V. cholerae* grow on TCBS as large, slightly flattened, yellow, smooth colonies with a diameter of 2-4 mm.

Identification of O1 or O139 serogroups is performed using slide agglutination test with antiserum raised against *V. cholerae* O1 or O139. Agglutination in polyvalent O1 antiserum provides presumptive identification of serogroup O1, which must then be confirmed by agglutination with monovalent Ogawa and Inaba antisera. Identification of serogroup O139 should be performed with specific O139 antiserum (Kay *et al.*, 1994).

A series of biochemical tests may be used for further identification in addition to serological identification. A crucial biochemical test for distinguishing *V. cholerae* from other members of *Enterobacteriaceae* is the oxidase test. *V. cholerae* is oxidase-positive while all *Enterobacteriaceae* are oxidase-negative. Other important traits that may be used to distinguish *V. cholerae* include fermentation of glucose with acid production (without gas), maltose, mannitol, sucrose and trehalose. In a string test, a loopful of *V. cholerae* suspended in a drop of 0.5% aqueous deoxycholate gives a mucoid “string” when drawn. Inoculation of *V. cholerae* into Kligler iron agar (KIA) or triple sugar iron agar (TSI) produces an alkaline slant (K) over acid (A) butt, with no gas or H<sub>2</sub>S (Kay *et al.*, 1994).

Conventional culture methods are time-consuming and labour-intensive. It takes at least 2 days to obtain results and may lack sensitivity, especially for poorly handled samples or clinical samples of patients previously treated with antibiotics as the number of viable and culturable organisms may be diminished. Detection may also be difficult if the number of viable organism is low, as in some environmental samples where *V. cholerae* can exist in a metabolic state that is non-culturable, but still remain viable and capable of causing disease (Colwell and Huq, 1994b).

## **1.11.2 Alternative methods of cholera diagnosis**

### **1.11.2.1 Immunological-based tests for cholera**

As an alternative to conventional culture methods, several rapid immunological-based tests have been developed. The earlier studies employed antibodies against *V. cholerae* O1 antigen in enzyme-linked immunosorbent assay (ELISA) format (Martinez-Govea *et al.*, 2001, Osek *et al.*, 1992, Bhadra *et al.*, 1991, Gustafsson, 1984, Cooper *et al.*, 1983), bead-ELISA format (Ramamurthy *et al.*, 1996, Ramamurthy *et al.*, 1992, Uesaka *et al.*, 1992, Cooper *et al.*, 1983), immunofluorescence microscopy (Goel *et al.*, 2005, Hasan *et al.*, 1994a, Huq *et al.*, 1990), coagglutination test (Goel *et al.*, 2005, Hasan *et al.*, 1995, Colwell *et al.*, 1992, Rahman *et al.*, 1989, Rahman *et al.*, 1987) and colloidal gold-based colorimetric immunoassay (Hasan *et al.*, 1994b). Immunoassays for *V. cholerae* O139 have also been developed using coagglutination test (Qadri *et al.*, 1994), immunofluorescence microscopy (Hasan *et al.*, 1995), colloidal gold-based colorimetric test (Qadri *et al.*, 1995) and dot-blot ELISA (Chaicumpa *et al.*, 1998).

More recently, antibody-based biosensors, called immunosensors, have been described. Jyoung *et al.* (2006) immobilized monoclonal antibodies against *V. cholerae* O1 on a self-assembled monolayer (SAM), whereby binding of O1 antigen to the antibody can be detected using surface plasmon resonance (SPR) spectroscopy. Rao *et al.* (2006) utilized an indirect ELISA method in developing an amperometric immunosensor for detection of *V. cholerae* O1 on disposable screen-printed electrodes.

Most of the immunological assays offer the advantages of speed, simpler reagents and equipments, better sensitivity and specificity over culture methods. Several tests such as CholeraScreen, Cholera DFA and Cholera SMART have been reported to be able to detect VBNC cells from faecal specimens (Colwell and Huq, 1994b). However, only a few tests are commercially available, namely SMART<sup>TM</sup> and Medicos<sup>TM</sup> Cholera Dipstick to detect the O1 serogroup but these tests are quite expensive and well beyond the reach of medical providers in areas at risk of cholera (Kalluri *et al.*, 2006).



### 1.11.2.2 Molecular-based tests for cholera

Recently, there has been a move to adopt molecular-based methods as a gold standard to replace the traditional culture methods. The use of molecular techniques that rely on nucleic acid amplification, such as polymerase chain reaction (PCR), ligase chain reaction (LCR), transcription-mediated amplification (TMA), strand displacement amplification (SDA) and nucleic acid sequence-based amplification (NASBA) have greatly improved the speed, sensitivity and specificity of diagnostic tests. This, in turn, would facilitate early and informed decision-making related to patient management, infection control, treatment and prevention.

PCR assays have been developed to detect the cholera enterotoxin operon, since most of the cholera pandemic and epidemics were associated with enterotoxin producing *V. cholerae* (Koch *et al.*, 1993, Fields *et al.*, 1992, Shirai *et al.*, 1991). Subsequently, a multiplex PCR assay was developed to detect toxigenic strains of *V. cholerae* based on the cholera toxin gene and to identify its biotype based on the *hyl* gene (Shangkuan *et al.*, 1995).

As the new cholera pandemic involving the serogroup O139 began to emerge, various PCR tests were developed to detect this new serogroup O139 alone (Albert *et al.*, 1997), or both the serogroups O139 and O1 (Gubala, 2006, Lipp *et al.*, 2003, Lyon, 2001, Singh *et al.*, 2001, Albert *et al.*, 1997, Rivera *et al.*, 1995). Besides detecting the serogroups O1 and O139, Nandi *et al.* (2000) and Di Pinto *et al.* (2005) have developed PCR assays based on non-virulence genes such as the *ompW* and collagenase gene, respectively, which were able to detect certain non-toxigenic *V. cholerae* strains of the serogroups non-O1, non-O139. This serogroup is often found in environmental samples and causes sporadic and localized diarrheal outbreaks (Vital-Brazil *et al.*, 2002, Kaper *et al.*, 1994).

#### **1.11.2.2.1 Characteristics and advantages of molecular-based tests over conventional methods**

The advantage of PCR over conventional culturing in detecting viable but non-culturable (VBNC) cells of *V. cholerae* was proven in a study by Chaiyanan *et al.* (2001). Conservation of cholera toxin-associated genes like *ctxA*, *tcpA*, *toxR* and *zot* in chromosomal DNA of VBNC cells was demonstrated using PCR. It was shown that VBNC cells retained their viability, along with their genes and chromosomal integrity up to one year.

PCR assays are rapid, highly sensitive, specific and can detect more than one gene at the same time. Although the advantages of PCR-based test over conventional culture method are numerous, there are certain limitations to the test. PCR requires the use of a thermal cycler and even with recent advances in this field, the cost and size of a thermal cycler limit its use in laboratories with limited resources (Lai *et al.*, 2006). In addition, PCR reagents must be transported and stored at  $-20^{\circ}\text{C}$  and maintaining a constant cold chain may not be possible when transporting to far or remote places.

These are important considerations in developing a diagnostic test for cholera, as cholera is a disease that affects most of the poor under-developed countries, or countries ravaged by war or natural disasters. Hence, there are not many PCR-based tests for cholera in the market, while those that are available commercially are immunochromatographic-based assays, which can be quite expensive and still require refrigeration for long term storage (Kalluri *et al.*, 2006).

PCR can amplify DNA from both live (viable) and dead (non-viable) cells, since DNA can remain intact and undegraded long after cell death. Thus, PCR-based tests cannot differentiate viable from non-viable cells. Since cholera is transmitted mainly by contaminated food and water, detection of viable cells from these samples is desirable during an epidemic to identify the source of infection and implement control measures. It is important that positive test results are associated with live cells and not the remains of dead cell. Identification of live cells would also help clinicians in monitoring the effectiveness of

antimicrobial treatments in patients (Bej *et al.*, 1996). Detection of viable microorganisms after sterilization procedures is also important in the medical and food industry to ensure effectiveness of the process.

RNA has been suggested as a suitable indicator of cell viability as it rapidly degrades after cell death (Sheridan *et al.*, 1999, Sheridan *et al.*, 1998). Detection of RNA is possible through reverse-transcription PCR (RT-PCR), a modification of the PCR process, which first converts the RNA to cDNA, and subsequently the cDNA is amplified by PCR. RT-PCR is a multiple step process and even small amounts of DNA in the RNA sample might get amplified, thus giving a false-positive result. Therefore, all RNA samples need to be treated with DNase enzyme prior to RT-PCR.

#### **1.11.2.3 Nucleic acid sequence-based amplification (NASBA)**

Besides RT-PCR, another RNA-based amplification technique is nucleic acid sequence-based amplification (NASBA). NASBA is an isothermal amplification assay that specifically amplifies RNA. The reaction occurs at a relatively low temperature of 41°C that does not promote the denaturation of double-stranded DNA, hence DNA is not amplified (Deiman *et al.*, 2002). Furthermore, it can be performed using a simple water bath or heating block. NASBA produces more amplicons in a shorter time than PCR, requiring only 60 – 90 minutes of assay time, compared to 2 – 3 hours for RT-PCR. Amplification of approximately  $10^6$  to  $10^9$ -fold is obtained within 90 minutes (Compton, 1991).

The single-stranded RNA amplicons can be detected using various methods, such as agarose gel electrophoresis (Jean *et al.*, 2004, Jean *et al.*, 2002b), molecular beacon-based real-time amplification technique (Loens *et al.*, 2008, Churruca *et al.*, 2007, Deiman *et al.*, 2007, Fykse *et al.*, 2007, Nadal *et al.*, 2007) and probe hybridisation techniques, such as Northern blotting (Jean *et al.*, 2004, Jean *et al.*, 2002b), ELISA (Lau *et al.*, 2008, Jean *et al.*, 2002a, Jean *et al.*, 2002b), electrochemiluminescence (ECL) (Lau *et al.*, 2008, Collins *et al.*, 2003, Hibbitts *et al.*, 2003), enzyme-linked gel assay (ELGA) (Lau *et al.*, 2008, Hibbitts *et*

*et al.*, 2003) and biosensors (Baumner *et al.*, 2004a, Baumner *et al.*, 2004b, Zaytseva *et al.*, 2004). These features make NASBA a suitable molecular-based test for cholera. Figure 1.1 shows an overview of the NASBA reaction.

NASBA was first reviewed in 1991 by Compton (1991), who described the salient features of the technology and its applications. Kievits *et al.* (1991) was among the earliest to describe the use of NASBA for the diagnosis of HIV-1 infection. Since NASBA is an RNA amplification technology, it is suitable for detection of RNA viruses, such as norovirus (Kou *et al.*, 2006, Patterson *et al.*, 2006, Rutjes *et al.*, 2006), enterovirus (Casper *et al.*, 2005, Landry *et al.*, 2005), hepatitis A virus (Abd el-Galil *et al.*, 2005) and cytomegalovirus (Bergallo *et al.*, 2006, Revello *et al.*, 2003).

NASBA provided researchers with a way of detecting viable microorganisms in clinical samples, food and environmental samples, as presence of intact RNA is a valuable indicator of viability. Detection of viable microorganisms is important for screening of contaminated food (Cook, 2003, Gore *et al.*, 2003) and environmental samples (Fykse *et al.*, 2007, Rutjes *et al.*, 2006, Baumner *et al.*, 2003); monitoring the clinical course of a disease (Yoo *et al.*, 2005); and assessing the efficacy of antimicrobials and other treatments (de Vries *et al.*, 2006).

A real-time NASBA assay for *V. cholerae* was developed by Fykse *et al.* (2007) targeting genes encoding cholera (*ctxA*), toxin-corregulated pilus (*tcpA*), *ctxA* toxin regulator (*toxR*), hemolysin (*hlyA*) and the 60 kDa chaperonin product (*groEL*). The assay was able to detect *V. cholerae* from various environmental water samples and has a strong potential for detecting toxigenic strains using the *tcpA* and *ctxA* markers.

Besides detection of medically important microorganisms, other clinical applications of NASBA include detection of biomarkers and important human genes. NASBA has also been used to detect disease-causing microorganisms in the marine, agriculture and livestock industries (Lau *et al.*, 2008, Lau *et al.*, 2006, Olmos *et al.*, 2007, Teng *et al.*, 2006).




Figure 1.1: Overview of the NASBA reaction

### 1.12 Rationale of the study

Most of the molecular-based diagnostic tests that have been developed for *V. cholerae* are either PCR or real-time based PCR assays. These assays require constant cold chain for transport and storage of the PCR reagents, skilled laboratory technicians and sophisticated equipments to perform the tests. Moreover PCR assays detect DNA, which may still be present in dead cells; therefore it cannot be used to differentiate between viable and non-viable cells. Identification of viable *V. cholerae* is important especially during a cholera epidemic, where detection of viable cells from food and water samples is desirable to identify the source of infection and implement control measures. It is also useful for testing environmental samples for reservoirs of viable *V. cholerae*.

We have identified a non-virulence gene called *lolB* (*hemM*), which codes for an outer membrane protein in *V. cholerae*. The *lolB* gene sequence has been submitted to the Genbank under the accession number AF227752. The *lolB* gene sequence was found to be highly conserved among the different serogroups of *V. cholerae*. A PCR assay was developed that was able to detect O1, O139 and non-O1, non-O139 serogroups of *V. cholerae* from clinical and environmental samples with 98.5% sensitivity and 100% specificity (Lalitha *et al.*, 2008).

The present study used the *lolB* gene as a candidate in the development of a cholera NASBA-ELISA assay for detection of *V. cholerae*. The cholera NASBA-ELISA assay with biosensor detection would be a suitable detection method for viable *V. cholerae* as it does not require expensive and specialized equipments. The present study also aims to make NASBA easy to perform and to eliminate the need for cold storage of NASBA reagents through the use of our patent-pending thermostabilization technology (Ravichandran *et al.*, 2005), which has been successfully applied in thermostabilization PCR assays for typhoid and cholera (Aziah *et al.*, 2007, Ravichandran *et al.*, 2003). To the best of our knowledge, this is the first time a thermostabilized cholera NASBA-ELISA assay featuring the use of a portable biosensor is described.

### **1.13 Objectives of the study**

#### **Phase 1: Development and optimization of a cholera NASBA assay**

1. To design specific primers and probes for cholera NASBA assay
2. To construct *in vitro* RNA transcripts as positive control
3. To develop and optimize a cholera NASBA assay targeting the *lolB* gene of *V. cholerae*
4. To analyze the NASBA reaction and its amplicons
5. To test the suitability of *lolB* mRNA as an indicator of cell viability

#### **Phase 2: Development and optimization of ELISA for detection of cholera NASBA amplicons (cholera NASBA-ELISA)**

6. To develop and to optimize an ELISA test for detection of NASBA amplicons by comparison of two ELISA formats
7. To evaluate the cholera NASBA-ELISA assay with spiked stool samples
8. To calculate the diagnostic sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the clinical evaluation


#### **Phase 3: Development of an electrochemical biosensor detection for cholera NASBA ELISA assay**

9. To optimize detection of the NASBA-ELISA signal with an electrochemical biosensor
10. To compare the biosensor results with spectrophotometric measurements

#### **Phase 4: Optimization of a thermostabilized NASBA mix**

10. To optimize the enzymes and enzyme stabilizer concentrations for thermostabilization of the NASBA mix
11. To determine the stability of the thermostabilized NASBA mix stored at different temperatures over a certain period of time

### 1.14 Overview of the study





## **CHAPTER 2**

### **MATERIALS AND METHODS**

#### **2.1 Materials**

##### **2.1.1 Bacterial strains**

###### **2.1.1.1 Reference strains**

Six *V. cholerae* strains comprising of O1, O139 and non-O1, non-O139 serogroups were used as reference strains for optimization and evaluation of the sensitivity of the NASBA assay. Six other *Vibrio* species strains and 29 enteric pathogen strains were used as reference strains for evaluating the specificity of the NASBA assay. The *V. cholerae*, *Vibrio* spp. and 10 enteric pathogen strains were obtained from Prof. Mitsuaki Nishibuchi, Centre for Southeast Asia Studies, Kyoto University, Japan as a gift. The remaining 19 enteric pathogen strains were obtained from the culture collection of the Department of Microbiology and Parasitology, Universiti Sains Malaysia, Malaysia. Details of the reference strains used in this study are given in table 2.1.

###### **2.1.1.2 Clinical isolates**

For evaluation of the NASBA assay using spiked stool samples, 110 well-characterized strains of *V. cholerae* isolated from clinical samples were obtained from Centre for Southeast Asia Studies, Kyoto University, Japan; Communicable Diseases Hospital, Thandiarpettai, Chennai, India; Hospital Universiti Sains Malaysia (HUSM) and General Hospital Kota Bharu (GHKB), Kota Bharu, Kelantan; National Public Health Laboratory (MKAK), Ministry of Health, Sungai Buloh; and Institute for Medical Research (IMR), Selangor, Malaysia.

In addition, 45 well-characterized strains of other *Vibrio* species and various enteric pathogens isolated from clinical samples were also obtained from Centre for Southeast Asia Studies, Kyoto University, Japan; Hospital Universiti Sains Malaysia (HUSM), Kota Bharu, Kelantan and Institute of Medical Research (IMR), Selangor, Malaysia.

All 41 reference strains were also included in the evaluation of the NASBA assay using spiked stool samples as these were originally isolated from clinical samples. Details of the clinical isolates used in the study are given in table 2.2.

### **2.1.1.3 Growth and maintenance of bacterial strains**

All bacterial strains were preserved and maintained as glycerol stock in LB broth with 15% glycerol and kept at -70°C. For experimental purposes, the bacterial strains were revived from glycerol stocks by inoculating a loopful of culture into LB broth and incubated overnight at 37°C. For *V. cholerae* strains, the overnight cultures were then subcultured onto TCBS agar while for other enteric bacteria, the overnight cultures were subcultured onto LB agar and incubated overnight at 37°C. *V. cholerae* appeared as yellow, convexed and mucoid colonies on TCBS agar. A single colony was picked with a sterile wire loop, streaked onto LB agar and incubated overnight at 37°C again. These cultures were used to perform the NASBA assay.

### **2.1.2 Culture Media**

Culture media were prepared using molecular biology or biotechnology grade chemicals. Distilled water was used for preparing media solutions. The appropriate media were autoclaved at 121°C, 15 psi for 15 minutes. Sterility check was performed by incubating the media at 37°C overnight. Sterile agar media were stored at 4°C while broth and other liquid media were stored at room temperature. The list of culture media used in this study is given in appendix A.

**Table 2.1: Details of the reference strains used in this study**

Reference strains	Source	Serogroup or species	No. of strains	
<i>Vibrio cholerae</i> (n = 6)	Centre for Southeast Asia Studies, Kyoto University, Japan	<i>V. cholerae</i> , O1 Classical	2	
		<i>V. cholerae</i> , O1 El Tor	2	
		<i>V. cholerae</i> , O139 Bengal	1	
		<i>V. cholerae</i> , non-O1, non-O139	1	
Other <i>Vibrio</i> spp. (n = 6)	Centre for Southeast Asia Studies, Kyoto University, Japan	<i>V. cincinnatiensis</i>	1	
		<i>V. fluvialis</i>	1	
		<i>V. furnissii</i>	1	
		<i>V. mimicus</i>	1	
		<i>V. parahaemolyticus</i>	1	
		<i>V. vulnificus</i>	1	
Enteric pathogens (n = 29)	Centre for Southeast Asia Studies, Kyoto University, Japan	<i>Aeromonas hydrophila</i>	1	
		<i>Escherichia coli</i>	2	
		<i>Pleisiomonas shigelloides</i>	1	
		<i>Salmonella enteritidis</i>	1	
		<i>Salmonella typhi</i>	1	
		<i>Shigella boydii</i>	1	
		<i>Shigella dysenteriae</i>	1	
		<i>Shigella flexneri</i>	1	
		<i>Shigella sonnei</i>	1	
		Department of Microbiology and Parasitology, Universiti Sains Malaysia	<i>Acinetobacter</i> spp.	1
			<i>Acinetobacter baumannii</i>	1
	<i>Bacillus cereus</i>		1	
	<i>Bacillus subtilis</i>		1	
	<i>Burkholderia pseudomallei</i>		1	
	<i>Citrobacter freundii</i>		1	
	<i>Enterobacter cloacae</i>		1	
	<i>Klebsiella</i> spp.		1	
	<i>Klebsiella pneumoniae</i>		1	
	<i>Morganella morganii</i>		1	
	<i>Proteus mirabilis</i>		1	
	<i>Proteus vulgaris</i>	1		
	<i>Providencia stuartii</i>	1		
<i>Pseudomonas aeruginosa</i>	1			
<i>Salmonella</i> spp.	1			
<i>Salmonella para typhi</i> A	1			
<i>Salmonella para typhi</i> B	1			
<i>Serratia marsescens</i>	1			
<i>Yersinia enterocolitica</i>	1			
<b>TOTAL</b>			<b>41</b>	

**Table 2.2: Details of the clinical isolates used in this study**

Clinical isolates	Source	Serogroup or species	No. of isolates
<i>Vibrio cholerae</i> (n = 116)	Hospital Universiti Sains Malaysia (HUSM), Kelantan, Malaysia	<i>V. cholerae</i> , O1	8
	General Hospital, Kota Bharu (GHKB), Kelantan, Malaysia	<i>V. cholerae</i> , O1	17
	National Public Health Laboratory, Ministry of Health, Sungai Buloh, Selangor, Malaysia	<i>V. cholerae</i> , O1	6
	Institute for Medical Research (IMR), Selangor, Malaysia	<i>V. cholerae</i> , O1	55
		<i>V. cholerae</i> , O139 Bengal	1
		<i>V. cholerae</i> , non-O1, non-O139	3
	Communicable Diseases Hospital, Thandiarpettai, Chennai, India	<i>V. cholerae</i> , O139 Bengal	9
Centre for Southeast Asia Studies, Kyoto University, Japan	<i>V. cholerae</i> , O1	14	
	<i>V. cholerae</i> , O139 Bengal	2	
	<i>V. cholerae</i> , non-O1, non-O139	1	
Other <i>Vibrio</i> spp. (n =12)	Centre for Southeast Asia Studies, Kyoto University, Japan	<i>V. cincinnatiensis</i>	1
		<i>V. fluvialis</i>	3
		<i>V. furnissii</i>	2
		<i>V. mimicus</i>	2
		<i>V. parahaemolyticus</i>	1
		<i>V. vulnificus</i>	2
	Institute for Medical Research (IMR), Selangor, Malaysia	<i>V. vulnificus</i>	1
Enteric pathogens (n = 68)	Centre for Southeast Asia Studies, Kyoto University, Japan	<i>Aeromonas hydrophila</i>	1
		<i>Escherichia coli</i>	4
		<i>Pleisiomonas shigelloides</i>	1
		<i>Salmonella enteritidis</i>	1
		<i>Salmonella typhi</i>	1
		<i>Shigella boydii</i>	1
		<i>Shigella dysenteriae</i>	1
		<i>Shigella flexneri</i>	1
		<i>Shigella sonnei</i>	1

Table 2.2 (continued)

Clinical isolates	Source	Serogroup or species	No. of isolates
Enteric pathogens (n = 68)	Department of Microbiology and Parasitology, Universiti Sains Malaysia	<i>Acinetobacter</i> spp.	1
		<i>Acinetobacter baumannii</i>	1
		<i>Bacillus cereus</i>	1
		<i>Bacillus subtilis</i>	1
		<i>Burkholderia pseudomallei</i>	1
		<i>Citrobacter freundii</i>	2
		<i>Enterobacter cloacae</i>	1
		<i>Escherichia coli</i>	1
		<i>Klebsiella</i> spp.	1
		<i>Klebsiella pneumoniae</i>	1
		<i>Morganella morganii</i>	1
		<i>Proteus vulgaris</i>	1
		<i>Pseudomonas aeruginosa</i>	2
		<i>Salmonella enteritidis</i>	1
		<i>Salmonella typhi</i>	1
		<i>Serratia marsecens</i>	1
		<i>Shigella boydii</i>	1
		<i>Staphylococcus aureus</i>	1
	<i>Streptococcus</i> group G	1	
	Institute for Medical Research (IMR), Selangor, Malaysia	<i>Aeromonas hydrophila</i>	1
		<i>Acinetobacter baumannii</i>	1
		<i>Bacillus cereus</i>	1
		<i>Burkholderia pseudomallei</i>	1
		<i>Enterococcus faecalis</i>	1
		<i>Klebsiella</i> spp.	1
		<i>Klebsiella pneumoniae</i>	1
		<i>Proteus mirabilis</i>	1
		<i>Providencia stuartii</i>	1
		<i>Salmonella</i> spp.	4
		<i>Salmonella enteritidis</i>	1
		<i>Salmonella para typhi</i> A	5
		<i>Salmonella para typhi</i> B	3
		<i>Salmonella typhi</i>	4
<i>Shigella boydii</i>		2	
<i>Shigella dysenteriae</i>	2		
<i>Shigella flexneri</i>	1		
<i>Shigella sonnei</i>	2		
<i>Staphylococcus aureus</i>	1		
<i>Yersinia enterocolitica</i>	1		
<b>TOTAL</b>		<b>196</b>	